L-trans-Pyrrolidine-2,4-dicarboxylic acid, EAAT2, EAAT4 and EAAT5 inhibitor

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

Glutamate Transporter 1 (GLT-1) also recognized as Excitatory Amino Acid Transporter 2 (EAAT2) is essential for regulating the levels of glutamate in the central nervous system. This protein features a mass of approximately 70 kDa and is largely expressed in astrocytes within the brain. It operates by transporting glutamate from the extracellular space into the cells utilizing the sodium concentration gradient as a driving force. This active transport mechanism prevents the accumulation of glutamate in the synaptic cleft reducing excitotoxicity which is harmful to neural cells.

Biological function summary

GLT-1 serves to maintain neurotransmitter homeostasis critical for proper synaptic functioning. It is a part of the larger SLC1 (solute carrier family 1) protein family which includes other transporters with similar functions. GLT-1 works closely with other glutamate transporters to help ensure synaptic signalings such as sensory perception and cognition proceed without interruption or damage. By efficiently clearing excessive glutamate from synapses it helps protect neurons from excitotoxic stress which can lead to cell death.

Pathways

This transporter is integral in the glutamatergic signaling pathway which plays an important role in synaptic plasticity and memory formation. GLT-1 closely interacts with proteins involved in metabolic pathways such as the glutamate-glutamine cycle ensuring that glutamate is recycled efficiently without causing cellular stress. It is also linked with EAAT1 another member of the excitatory amino acid transporters working in tandem to modulate the balance of neurotransmitter levels.

Associated diseases and disorders

Mutations or dysfunctions of GLT-1 have been implicated in neurological conditions such as amyotrophic lateral sclerosis (ALS) and epilepsy. In ALS the downregulation of GLT-1 can lead to insufficient clearance of glutamate contributing to motor neuron degeneration. This protein is additionally associated with EAAT2 which is often studied for its role in preventing excitotoxic damage that might exacerbate these neurologic conditions. Researchers are exploring therapeutics like riluzole to modulate GLT-1 activity and alleviate symptoms related to these diseases.